Oramed Pharmaceuticals, Inc ORMP

NAS: ORMP | ISIN: US68403P2039 20:10

2,370 USD (+3,04%)

(+3,04%) 20:10

Grafiek Oramed Pharmaceuticals, Inc

Grafiek Oramed Pharmaceuticals, Inc

1 dag1d 3,04%
1 week1w -1,66%
1 maand1m 1,72%
3 maanden3m -24,76%
6 maanden6m 9,72%
1 jaar1j -46,50%
5 jaar5j -22,45%

Oramed Pharmaceuticals, Inc in het nieuws

Toon enkel gratis nieuws

20 februari 2024 · Oramed Letter to Shareholders · Persbericht

2 augustus 2023 · Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally · Persbericht

20 juni 2023 · Oramed to Present at the 83rd American Diabetes Association Conference · Persbericht

18 mei 2023 · Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit · Persbericht

15 mei 2023 · Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China · Persbericht

1 mei 2023 · Oramed Appoints Ben Shapiro to its Board of Directors · Persbericht

9 februari 2023 · Oramed Pharmaceuticals Issues Shareholder Update · Persbericht

12 januari 2023 · Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes · Persbericht

4 januari 2023 · Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes · Persbericht

21 december 2022 · Oramed Letter to Shareholders · Persbericht

Profiel Oramed Pharmaceuticals, Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.oramed.com

Hoofdzetel: New York, New York Verenigde Staten

CEO: Nadav Kidron

Werknemers: 19

Aandelen Oramed Pharmaceuticals, Inc

Beurswaarde: 93,45 miljoen USD

Effecten: 40,63 miljoen

Beta: 1,14

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe